Evox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, snaring an $882 million partnership with Takeda for up to five rare disease programmes. The alliance ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

3382.T Seven & i Holdings Co., Ltd.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Takeda is sharpening its oncology focus amid ... expand their so-called Tech Lane cell therapy facility in Belgium. The plant is slated to begin clinical production of Carvykti in a few weeks.

Plant-based diets have soared in popularity as people look for ways to improve their health, reduce their carbon footprint, and consume less (or no) animal products. But while following plant ...